Gilead Sciences, a leading biopharmaceutical company, is set to initiate clinical trials for a groundbreaking HIV prevention shot, administered once a year. This innovative treatment aims to provide a more convenient and effective alternative to existing daily pills, offering a significant advancement in the fight against HIV.
Tag: Gilead Sciences
Gilead Sciences to Initiate Clinical Trials for Long-Acting HIV Prevention Injection
Gilead Sciences, a leading biopharmaceutical company, has announced plans to begin clinical trials for a long-acting injectable HIV prevention treatment. The once-yearly shot aims to provide individuals with a convenient and effective way to protect themselves against HIV infection.